The finding of multiple genome-wide significant hits in genes that encode proteins tightly involved in the formation (NOS3 (ref. 22), GUCY1A1 (ref. 4)), fate (PDE5A23,24), or mediating the downstream effects of cGMP (IRAG1 (ref. 14), PDE3A33) and the observation that sGC levels are reduced in atherosclerotic tissues34 increase the likelihood that targeting sGC might be beneficial in CAD. This evidence concerns the gene SGCB and coronary artery disorder.